Quest PharmaTech (CVE:QPT) Stock Price Down 25% – Time to Sell?

Quest PharmaTech Inc. (CVE:QPTGet Free Report) shares dropped 25% during trading on Thursday . The company traded as low as C$0.03 and last traded at C$0.03. Approximately 123,238 shares changed hands during trading, an increase of 414% from the average daily volume of 23,982 shares. The stock had previously closed at C$0.04.

Quest PharmaTech Trading Down 25.0%

The firm has a market cap of C$5.07 million, a price-to-earnings ratio of -30.00 and a beta of 0.00. The company has a quick ratio of 0.52, a current ratio of 0.40 and a debt-to-equity ratio of 4.35. The business has a 50 day moving average price of C$0.04 and a 200-day moving average price of C$0.04.

Quest PharmaTech Company Profile

(Get Free Report)

Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.

Further Reading

Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.